Article
Differential Effects of Dapagliflozin on Cardiovascular Risk Factors at Varying Degrees of Renal Function.
Clin J Am Soc Nephrol. 2017 May 8; 12 (5): 751-759.
Review
Renoprotective Effects of SGLT2 Inhibitors: Beyond Glucose Reabsorption Inhibition.
Curr Vasc Pharmacol. 2017 Jan 1; 15 (2): 96-102.
Review
Empagliflozin: a new treatment option for patients with type 2 diabetes mellitus.
Drugs Today. 2015 Sep 1; 51 (9): 519-35.